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Objective: To determine clinical predictors of lithium response in
bipolar disorder.
Methods: Systematic review of studies examining clinical predictors of
lithium response was conducted. Meta-analyses were performed when
≥2 studies examined the same potential predictor.
Results: A total of 71 studies, including over 12 000 patients, identiﬁed
six predictors of good response: mania-depression-interval sequence
[odds ratio (OR): 4.27; 95% CI: 2.61, 6.97; P < 0.001], absence of rapid
cycling (OR for rapid cycling: 0.30; 95% CI: 0.17, 0.53; P < 0.001),
absence of psychotic symptoms (OR for psychotic symptoms: 0.52;
95% CI: 0.34, 0.79; P = 0.002), family history of bipolar disorder (OR:
1.61; 95% CI: 1.03, 2.52; P = 0.036), shorter prelithium illness duration
[standardised mean diﬀerence (SMD): 0.26; 95% CI: 0.41, 0.12;
P < 0.001] and later age of onset (SMD: 0.17; 95% CI: 0.02, 0.36;
P = 0.029). Additionally, higher body mass index was associated with
poor response in two studies (SMD: 0.61; 95% CI: 0.90, 0.32;
P < 0.001). There was weak evidence for number of episodes prior to
lithium treatment (SMD: 0.42; 95% CI: 0.84, 0.01; P = 0.046),
number of hospitalisations before lithium (SMD: 0.40; 95% CI:
0.81, 0.01; P = 0.055) and family history of lithium response (OR:
10.28; 95% CI: 0.66, 161.26; P = 0.097).
Conclusions: The relative importance of these clinical characteristics
should be interpreted with caution because of potential biases and
confounding.
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Summations
• Our results suggest that predictors of good response are (i) mania-depression-interval sequence, (ii)
absence of rapid cycling (iii) absence of psychotic symptoms, (iv) shorter prelithium illness duration,
(v) family history of bipolar disorder and (vi) later illness onset. Additional features which may be
related to response are body mass index, number of episodes before lithium treatment, number of
hospitalisations before lithium and family history of lithium response.
Limitations
• Very few of the studies explored the possibility of interdependence or interaction between predictors.
• Because of the limitations of the data, particularly the limited number of RCTs, it is diﬃcult to sepa-
rate predictors of lithium response from predictors of a benign illness course.
• Because of the low reliability of the results and the inability to eliminate biases, any clinical conclu-
sions relating to any single predictor should be made cautiously.
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Globally, guidelines recommend lithium as ﬁrst-line
maintenance treatment for bipolar disorder (BPD)
(1–3). While lithium has a higher complete response
rate than other mood stabiliser medication, only one
in three patients will respond well to the drug (4). A
number of studies have attempted to identify predic-
tors of response from biological, genetic, clinical and
psychosocial characteristics. A recent review of
biomarkers to predict lithium response was some-
what discouraging (5). Genome-wide association
studies have developed a polygenic risk score for
lithium response (6) and large biological marker
studies are just beginning (7). However, despite enor-
mous potential to improve our understanding of
the lithium-responding subtype of BPD, these
approaches are unlikely to be able classify responders
accurately without the inclusion of additional clinical
features (6). We identiﬁed four reviews of multiple
clinical lithium response markers, with the most
recent attempt to meta-analyses original studies pub-
lished in 2005 (8–11). These reviews are limited in
their scope as they are not systematic and fail to meet
PRISMA standards (12). Factors associated with
lithium response described in these reviews include
the course of illness, family history of bipolar disor-
der, family history of lithium response, age at illness
onset, number of bipolar hospitalisations, mania-de-
pression-interval (MDI) course sequence, depres-
sion-mania-interval (DMI), continuous cycling (CC)
(<4 episodes per year without euthymic intervals
(13)), rapid cycling (RC) (≥4 episodes per year (13))
and bipolar II disorder (BPD II). We also identiﬁed
reviews which examined single predictors: pretreat-
ment episode count (14) and episode sequence (15).
In the light of these issues, we systematically reviewed
the existing literature on clinical predictors of lithium
response in BPD and performed meta-analysis where
possible.
Methods
This systematic review followed the MOOSE
guidelines and PRISMA statement (12, 16).
Eligibility criteria
We included randomised trial and observational
studies, including adult participants diagnosed
with BPD receiving lithium monotherapy. Studies
that did not report separate analyses of patients
treated with lithium were excluded. Studies exam-
ining the use of lithium for other indications (such
as unipolar depression) were excluded. We consid-
ered studies to be eligible for inclusion if they
reported an association between patient level fac-
tors (e.g. age at illness onset) and any deﬁnition of
a lithium response (e.g. recurrence under lithium
treatment).
Information sources
We searched EMBASE, Medline and Web of
Science from inception to July 2018; the ﬁnal
search was performed on July 14, 2018. Additional
studies were identiﬁed through screening reference
lists of included studies and relevant papers. We
included only English language studies in humans.
Other articles relevant to this topic were searched
for via Google Scholar, using reference lists of rele-
vant studies.
Search
We used the following search terms to search all
trials registers and databases: [Lithium* OR
lithium blood level OR lithium carbonate OR
lithium citrate OR treatment response* OR drug
response* OR predictor*] AND [Bipolar disorder]
AND [observational stud* OR controlled clinical
trial* OR RCT OR randomised controlled trial*].
Study selection
Eligibility screening was performed independently
by three reviewers. The ﬁrst author (TPH) screened
the titles and abstracts of potential studies to deter-
mine inclusion, with a 20% random sample of
records independently screened by two reviewers
(AK and LS). Eligible studies were subsequently
conﬁrmed by the three reviewers (TPH, AK and
LS) who independently checked the full text of all
retrieved articles. Disagreement was resolved
through discussion and consensus between TPH,
AK, LS and JFH.
Data collection process
One reviewer (TPH) extracted the following data
from included studies and the second (LS) checked
the extracted data, including author details, year
of publication, types of study design, sample size,
interventions investigated, comparison, outcome
evaluation or deﬁnition of lithium response and
key ﬁnding. Disagreements were resolved by dis-
cussion between TPH, AK, LS and JFH.
Data items
Information was extracted from each included
study on: (i) characteristics of study participants
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(including sample size and number of lithium
responders and non-responders; (ii) intervention
details (dose, duration of lithium treatment); (iii)
deﬁnition of a treatment response (number of
recurrence under lithium treatment, reduction in
time spent in hospital under lithium treatment,
reduction of episode frequency, or improvement
during lithium treatment based on valid scales,
such as Illness severity index (ISI) (17), Aﬀective
Morbidity Index (AMI) (18) and ALDA scale
(19)); (vi) potential predictors examined; (v) sum-
mary results. Data sharing is not applicable to this
article as no new data were created or analysed in
this study.
Risk of bias in individual studies
Three reviewers (TPH, AK and LS) independently
rated each eligible study. The quality of each indi-
vidual study was evaluated using the modiﬁed
Downs and Black quality assessment scale
(Table S1), which consists of 26 questions to evalu-
ate both randomised and non-randomised studies
(20). Question 27 evaluating power was excluded
as power should not be part of quality assessment
as the aim of a meta-analysis is to detect an eﬀect
from inconclusive or underpowered studies. Each
criterion is worth one point, and a total score of 20
or above, between 15 and 19, and 14 or below is
considered a study of good, fair and poor quality
respectively. This quality assessment tool evaluates
study reporting, external and internal validity
including bias and confounding. Discrepancies
between the two reviewers were resolved by discus-
sion and consensus.
Synthesis of results and risk of bias across studies
Meta-analyses were performed after the four
assumptions of homogeneity were assessed: (i)
studies should be similar in terms of patients
recruited; (ii) studies should be comparing the
same intervention or exposure with similar con-
trols, (iii) studies should be reporting the same
outcomes, (iv) the eﬀect of a predictor should
ideally be in the same direction (21). Narrative
analysis was carried out along with meta-analy-
sis if only some of the included studies met all
of the criteria. For each meta-analysis, where
there were two or more studies using the same
sample of patients, we excluded the smaller or
earlier study.
Meta-analysis using the DerSimonian and Laird
random eﬀect model was conducted for each pre-
dictor because we assumed heterogeneity existed
across diﬀerent studies, given the deﬁnitions of
lithium response across studies were inconsistent
(22). For binary outcomes, results of the primary
studies were summarised as odds ratios (ORs). For
continuous outcomes, results of the primary stud-
ies were summarised in standardised mean diﬀer-
ence (SMD). Pooled ORs or SMDs and
corresponding 95% conﬁdence intervals were cal-
culated if two or more studies reported the same
clinical predictor.
A number of studies categorised patients with
BPD as ‘partial responder’ in addition to ‘respon-
der’ and ‘non-responder’. In order to conduct the
random-eﬀects pairwise analysis, we combined the
group ‘partial responder’ and ‘non-responder’ and
formed the group ‘partial or non-responder’ to
avoid chances of data contamination that might
impact the results of clinical predictors of lithium
responders. Heterogeneity for each predictor was
assessed using forest plots and a measure of incon-
sistency (I2). Publication bias was examined visu-
ally through evaluating funnel plots. Stata version
15 was used for all analyses.
Results
Studies included
Our search resulted in 3897 unique citations. Of
these, 3670 studies were excluded as the titles
and abstracts were not relevant to the research
topic, leaving 137 potentially eligible studies for
which the full text was reviewed (Fig. 1). At
this stage, 71 studies did not meet the inclusion
criteria. An additional ﬁve studies that met the
inclusion criteria were identiﬁed by checking the
references of relevant papers and searching via
Google Scholar. A total of 71 studies met all
inclusion criteria and were included in system-
atic review, and 44 of these provided data
which could be meta-analysed. These studies
are described in Table 1. Studies were excluded
from the meta-analysis if the population over-
lapped with another included study population
or if it was not possible to calculate the OR or
SMD. This meant two large studies using Dan-
ish population registers could not be included
(23, 24).
In total, 19 clinical variables were identiﬁed
from the articles and further assessed as predictors
of lithium response in at least two or more studies:
(i) age at study start, (ii) age at illness onset, (iii)
prelithium illness duration, (iv) number of episodes
prior lithium treatment, (v) number of hospitalisa-
tions prior to lithium, (vi) type of BPD (BPD I vs.
BPD II), (vii) interval course sequence (MDI vs.
DMI), (viii) CC, (ix) irregular sequence (IRR)
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(absence of any regular mania-depression-
sequence), (x) RC, (xi) index episode (mania vs.
depression), (xii) predominant polarity (mania vs
depression), (xiii) family history of any aﬀective
disorder, (xiv) family history of BPD, (xv) family
history of lithium response, (xvi) alcohol and drug
use, (xvii) psychotic symptoms, (xviii) sex and (xix)
body mass index (BMI).
Age at illness onset
A total of 21 studies explored the eﬀect of age
at illness onset; ﬁve studies (25–29) were
excluded because of insuﬃcient reporting; two
studies reported categorical age data rather than
continuous data and were therefore not
included in meta-analysis. The study by Okuma
and colleagues (30) categorised patients into
four age groups (>20; 21–30; 31–40; <40) and
found no association between age at illness
onset and lithium response. However, a similar
study conducted by Schurhoﬀ et al. (31) found
that late onset (40 years old or older) was asso-
ciated with good lithium response (P = 0.04).
Pooling the remaining 14 eligible studies, with a
total sample of 2063 patients, there was an
association between age at onset and treatment
response (SMD = 0.17; 95% CI: 0.02 to 0.33;
P = 0.029; Fig. 2, Figure S1), but heterogeneity
was high (I2 = 58.3.6%; P = 0.003). Of these
included studies, four found increasing age was
associated with increased chance of lithium
response (32–35) and one found increased age
was associated with a reduced chance of
response (4).
Age at study start
The association between age at study start and
lithium treatment response was quantiﬁed in 10
studies with a total sample of 1266 patients. A
medium level heterogeneity was observed
(I2 = 50.8%; P = 0.032). The pooled eﬀect esti-
mate suggested no association between study
admission age and lithium response (SMD: 0.02;
95% CI: 0.17 to 0.21; P = 0.851; Fig. 2, Fig-
ure S1).
Prelithium illness duration
Data from ﬁve studies with a sample of 931
patients were pooled (Table 1). Heterogeneity was
low (I2 = 0.0%; P = 0.701). The results suggested
that a short prelithium treatment illness duration
was associated with good lithium response
(SMD = 0.26; 95% CI: 0.41 to 0.12;
P < 0.001; Fig. 2, Figure S2). This was also true in
the study by Kessing and colleagues of 4714 indi-
viduals with BPD (24); those commenced on
lithium at ﬁrst contact had lower rates of non-re-
sponse compared to those commenced at later con-
tacts (HR 0.87, 95% CI 0.76 to 0.91, P < 0.0001).

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prediction of lithium response
Number of episodes prior lithium treatment
The impact of mean number of episodes prior to
lithium treatment on treatment response was
assessed in seven studies with a total sample of 824
(Table 1). Meta-analysis suggested that increased
number of mood episodes prior to commencing
lithium was weakly associated with reduced chance
of good response (SMD = 0.42; 95% CI: 0.84
to 0.01; P = 0.046; Fig. 2, Figure S3). Hetero-
geneity was high (I2 = 85.9%; P < 0.001).
Number of hospitalisations prior to lithium treatment
A combined sample of 673 patients from four stud-
ies contributed data on number of previous hospi-
talisations. Although two studies suggested fewer
hospitalisations were associated with good response
(36, 37), overall there was no evidence of a clear
association between number of hospitalisations and
lithium response SMD = 0.40; 95% CI: 0.81 to
0.01; P = 0.055; Fig. 2, Figure S3). In the Danish
population (23), increasing number of hospitalisa-
tions between diagnosis and starting lithium were
associated with increased rates on non-response
(HR 1.03, 95%CI 1.02 to 1.05,P = 0.0002).
Type of bipolar disorder
The association between BPD subtype and good
lithium response was quantiﬁed in 11 studies with
a total of 1556 patients. There was evidence of con-
siderable heterogeneity (I2 = 70.7%; P < 0.001)
across studies, and the result indicated insuﬃcient
evidence to support BPD I as a clinical predictor
of lithium response when comparing to patients
with BPD II (OR: 1.01; 95% CI: 0.58 to 1.76;
P = 0.971; Fig. 3, Figure S4).
At an individual level, two of the included stud-
ies suggested BPD I may be associated with a pref-
erential lithium response (32, 34) and three
suggested BPD II may be associated with a prefer-
ential lithium response (4, 33, 38).
Episode sequence
A total of six studies, including 340 patients, com-
pared MDI and DMI sequence. MDI patients
were more likely to be lithium responders than
DMI patients (OR 4.27; 95% CI 2.61 to 6.97;
P < 0.001; Fig. 3, Figure S5). Heterogeneity was
low (I2 = 0.0%; P = 0.680).
Fig. 2. Relationship between clinical
variables and lithium treatment
response – standardised mean
diﬀerence of continuous variables.
aonly two studies; bI2 > 50%.
Fig. 3. Relationship between clinical
variables and lithium treatment
response – odds ratios of binary




The impact of continuous cycling on lithium treat-
ment response was quantiﬁed in seven studies with
a total of 804 patients. Meta-analysis suggested no
association between continuous cycling and
response (OR: 0.65; 95% CI: 0.34 to 1.26;
P = 0.204; Fig. 3, Figure S6).
Irregular sequence
When the data from four studies of irregular
sequence were pooled together, heterogeneity was
low (I2 = 0.0%; P = 0.496), and there was no asso-
ciation with lithium response (OR: 1.13; 95% CI:
0.70 to 1.83; P = 0.628, Fig. 3, Figure S6).
Rapid cycling
The impact of the presence of RC on lithium
treatment response was quantiﬁed in nine studies
with a total of 1442 patients. Moderate hetero-
geneity was identiﬁed (I2 = 37.5.6%; P = 0.119).
The meta-analysis result indicated evidence that
patients displaying RC have reduced odds of
lithium response compared to those without RC
(OR: 0.30; 95% CI: 0.17 to 0.53; P < 0.001;
Fig. 3, Figure S6).
Polarity of index episode
There was no evidence of an association between
lithium response and manic index episode (OR:
1.12; 95% CI: 0.56 to 2.21; P = 0.753; Fig. 3, Fig-
ure S7). From six studies, one suggested a manic
index episode was a good predictor of response
(32) and one suggested a depressive index episode
was a good predictor (33). Others were inconclu-
sive, and heterogeneity was high (I2 = 73.7%;
P = 0.002). Kessing et al. found reduced rates of
non-response in individuals with a manic index
episode (HR 0.84, 95% CI 0.77 to 0.91) and ele-
vated rates in those with a depressive index episode
(HR 1.13, 95% CI 1.03 to 1.25) compared to those
whose index episode was ‘remission, other or
unspeciﬁed’. However, it is unclear who is included
in this reference category and there is potential
misclassiﬁcation because of the routine register-
based nature of the data source.
Predominant mood polarity
Predominant mania or depression was documented
in three studies with a total sample of 280 patients.
Overall, there was no evidence for an association
between lithium response and mania over
depression dominance (OR: 1.07; 95% CI: 0.07 to
15.74; P = 0.959; Fig. 3, Figure S8).
Included studies were contradictory; one study
found a strong association between predominant
mania and lithium non-response (OR: 0.10; 95%
CI: 0.04 to 0.25) (33), another found a strong asso-
ciation between predominant mania and lithium
response (OR: 4.79; 95% CI 1.54 to 14.91) (30).
Family history
Eight studies, including 714 individuals, con-
tributed to meta-analysis of the association
between family history of any aﬀective disorder
and lithium response. There was no evidence of an
association (OR: 1.13; 95% CI: 0.75 to 1.69;
P = 0.560; Fig. 3, Figure S9). Individuals with a
family history of bipolar disorder were more likely
to have a good response to lithium (10 studies,
1454 patients; OR: 1.61; 95% CI: 1.03 to 2.52;
P = 0.036; I2 = 43.5%; heterogeneity P = 0.068;
Fig. 3, Figure S9). One study, which could not be
combined in meta-analysis, runs contrary to this,
ﬁnding 88% of individuals without a family history
have a reduction in episode frequency during
lithium treatment, while only 68% of those with a
family history of BPD. Only two studies (79
patients) could be included in meta-analysis of fam-
ily history of lithium response. Both studies had
point estimates suggesting good lithium response in
family members may be associated with good
response in the index patient, however, conﬁdence
intervals overlapped no eﬀect (OR: 10.28; 95% CI:
0.66 to 161.26; P = 0.097, Fig. 3, Figure S9).
Alcohol and drug use
The association between alcohol and drug use and
lithium response was investigated in three studies
with a total sample of 540 patients. The results
showed a medium heterogeneity (I2 = 54.5%;
P = 0.111) and demonstrated no evidence to sug-
gest alcohol and drug use as a potential predictor
of lithium response (OR: 0.55; 95% CI: 0.23 to
1.34; P = 0.189; Fig. 3, Figure S10).
Psychotic symptoms
A total sample of 1066 patients from eight studies
were included in assessing psychotic symptoms.
Medium heterogeneity was observed (I2 = 42.8%;
P = 0.093), and the result suggested a strong asso-
ciation between psychotic symptoms and poor
response (OR: 0.52; 95% CI: 0.34 to 0.79;
P = 0.002; Fig. 3, Figure S11).
17
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Sex
The role of sex as a potential lithium response pre-
dictor was investigated 1,729 patients from 17 stud-
ies. Sex was not associated with lithium treatment
response (being male OR: 0.89; 95% CI: 0.68 to
1.15; P = 0.356; I2 = 22.7%; heterogeneity
P = 0.191; Fig. 3, Figure S12). However, the only
population-based study identiﬁed suggested an
association between being female and non-response
(HR 1.12, 95% CI 1.04 to 1.21, P = 0.002) (23).
Body mass index
BMI was investigated as a predictor in only two
studies including 336 patients. In both studies,
lower BMI was associated with better lithium
response (pooled SMD: 0.61; 95% CI: 0.90 to
0.32; P < 0.001; I2 = 0.0%; heterogeneity
P = 0.111 Fig. 2, Figure S13).
Further potential predictors
A study by Rybakowski et al. investigated the rela-
tionship between temperament and lithium
response (39). Data from 71 patients suggested that
lithium response was correlated positively with
hyperthymic score (r = 0.31; P = 0.009), and nega-
tively with anxiety and cyclothymic temperament
scores (r = 0.27; P = 0.022 and r = 0.26;
P = 0.032 respectively). We identiﬁed one other
study which examined personality traits and treat-
ment response (40). This study reported that
responders had higher dominance scores (P-
value < 0.05), lower neuroticism scores (P-
value < 0.01) and were less likely to have ‘deviant
personalities’ (P-value < 0.05). Social support was
examined in two studies with overlapping study
populations (36, 41) and a third study which pre-
sented results in a way that did not permit meta-
analysis. Lower social support was associated with
poor response in each case. Other sociodemo-
graphic characteristics were reported in a small
number of studies. Social class was associated with
response in one identiﬁed study, but not in another
(36, 42). Education, marital status, (38) and ethnic-
ity (43) were not associated with lithium response.
Employment status was associated with response in
one large nationwide population study (23), but
not in a smaller observational study (38). Insulin
resistance was found to be associated with poor
response to lithium in one study, in keeping with
the studies showing an association with BMI (47–
49). While we did not consider childhood trauma
as a ‘clinical’ predictor of treatment response, one
included study examined this among other features
(50). This study suggested physical abuse was an
independent predictor of poor lithium response
after accounting for many clinical characteristics.
However, the only other study we could identify
examining childhood trauma found no association
between lithium response and any type of trauma
(51).
Risk of bias within studies
Overall, the mean Downs and Black quality assess-
ment score was 16.3, which is considered fair qual-
ity. We identiﬁed eight good quality studies, 45 fair
quality studies and 18 poor quality studies (Tables
S1 and S2). Most of the studies failed to report or
account for appropriate confounders in regression
analyses.
Risk of bias across studies
In line with the Sterne et al. (52), funnel plot asym-
metry was assessed when 10 or more studies were
included in the meta-analysis. Funnel plots were
produced for age at illness onset (Figure S14), sex
(Figure S15), family history of BPD (Figure S16),
age at study start (Figure S17) and type of BPD
(Figure S18). The studies of BPD subtype, sex and
family history produced asymmetrical funnel plots.
A possible source of this asymmetry is true hetero-
geneity between studies; potentially because of dif-
ferences in lithium dosage, treatment duration or
diagnostic deﬁnition, small sample sizes and the
low number of studies included.
Discussion
We identiﬁed a total of 71 studies, including over
12 000 patients which explore clinical predictors of
lithium treatment response in patients with BPD.
From these, six predictors of good response were
identiﬁed. Our results suggest that predictors of
good response are (i) MDI sequence, (ii) absence
of RC, (iii) absence of psychotic symptoms, (iv)
shorter prelithium illness duration, (v) family his-
tory of bipolar disorder and (vi) later illness onset.
Additional features which may be related to
response are body mass index, number of episodes
before lithium treatment, number of hospitalisa-
tions before lithium and family history of lithium
response.
Our ﬁndings generally correspond with previous
review articles (8–11). As far as we are aware,
Kleindienst et al. conducted the only previous
meta-analysis of multiple clinical response predic-
tors and our results were broadly similar (8).
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However, we did not ﬁnd a strong association with
number of previous hospitalisations or CC, and
they found no association with prelithium illness
duration, psychotic symptoms or RC. This may be
because of diﬀering approaches to study inclusion
and analysis, and in some cases because contradic-
tory results have been found in individual studies
published since 2005. Additionally, prelithium ill-
ness duration, number of episodes prior to lithium
treatment and number of hosptialisations prior to
lithium are likely to all be measuring a similar
underlying concept.
Clinically, these predictors are likely to be of
varying importance. Some may essentially reﬂect
establishing a more benign illness course because
of early intervention and may not be speciﬁc to
lithium. This may be the case for shorter pre-
lithium illness duration, and fewer episodes prior
to lithium treatment, which are clearly related to
illness severity. Others may be more central to
guiding the choice to use lithium. DMI sequence,
rapid cycling and psychotic symptoms are all asso-
ciated with poor lithium response, so their pres-
ence may suggest an alternative treatment might
be more appropriate for the patient. However,
there is limited evidence to suggest any other drug
therapy would lead to better than responses than
with lithium. Family history of bipolar disorder
and potentially family history of lithium response
(likely under powered in our analysis) are impor-
tant as they may reﬂect a more heritable subtype
of BPD.
Limitations
The reliability of the potential predictors identi-
ﬁed remains unclear. For most of the meta-anal-
yses conducted, estimates were highly
heterogeneous, often including studies suggesting
both a positive and negative eﬀect of the predic-
tor. Most studies were rated as fair or poor in
terms of quality. Often insuﬃcient statistical
information was reported in the primary study
to conduct meta-analysis; most studies failed to
report adequate summary statistics such as stan-
dard deviation or number of responders and
non-responders. Sample sizes were often small
and studies consisted of highly selective groups
of patients. Also, the deﬁnition of lithium
response in many of the studies did not rely on
a standardised tool, which can greatly inﬂuence
the process of identifying lithium responders and
lithium non-responders. As shown in Table 1,
most of the studies relied on recurrence of an
aﬀective episode under lithium treatment to
deﬁne lithium non-responders. However, this
deﬁnition of lithium response fails to consider
changes in episode frequency or symptom sever-
ity, and so may miscategorise responders and
non-responders. Scott and colleagues note that
using continuous scores for lithium response as
opposed to categories of response leads to diﬀer-
ent predictors being identiﬁed (53). Additionally,
none of the studies reported lithium plasma level
or adherence to treatment by response status.
Information on these factors would strengthen
the argument that these are true predictors of
lithium response as it would then be possible to
rule out diﬀerences in the way treatment is used
as a cause of the observed associations.
Very few of the studies explored the possibility of
interdependence or interaction between predictors.
For example, interdependence might exist between
prelithium illness duration and illness severity (54).
A greater illness severity is related to receiving early
treatment and subsequently decreasing illness mor-
bidity. Accordingly, a short prelithium illness dura-
tion might appear to be related to good lithium
response (54). Only some of the more recent studies
included multiple covariates in the same model (for
example; (23, 50, 53)) an approach which is neces-
sary to determine whether covariates are truly inde-
pendent predictors.
Because of the low reliability of the results
and the inability to eliminate biases, any clinical
conclusions relating to any single predictor
should be made cautiously. Because of the limi-
tations of the data, particularly the limited num-
ber of RCTs, it is diﬃcult to separate predictors
of lithium response from predictors of a benign
illness course.
In conclude although we identiﬁed six potential
clinical predictors of lithium response, there are a
number of issues relating to their reliability and
validity which cannot be addressed by reviewing
the existing literature. As with response classiﬁca-
tion by genetic or biological markers, clinical
response prediction is likely to be complex and
multivariable. Studies need to explore multiple pre-
dictors, and their interactions, with operationalised
end points for lithium response.
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